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in DCV+SOF (LE= 19.02, QALE= 12.52) compared to SOF+RBV (LE= 18.66, QALE= 12.08), 
respectively. In GT3, overall predicted costs were also lower with DCV+SOF (£315,416) 
compared to SOF+RBV (£330,737). CONCLUSIONS: In those co-infected with HIV and 
GT1 or 3 HCV, 12 weeks of treatment with DCV+SOF was predicted to be dominant 
(increased QALE with decreased costs) compared to 24 weeks of SOF+RBV.
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OBJECTIVES: The availability of effective treatment for chronic hepatitis C patients 
with advanced disease is an area of unmet medical need. The objective of this 
study was to assess the cost-effectiveness of daclatasvir+sofosbuvir (DCV+SOF) for 
the treatment of hepatitis C virus (HCV) genotypes (GT) 1, 3 and 4 in patients with 
advanced disease (METAVIR score ≥ F3) compared to standard of care. METHODS: 
DCV+SOF was compared to telaprevir+pegylated interferon-alfa+ribavirin (TVR+PR) 
and no treatment (NT) in GT1, and pegylated interferon-alfa+ribavirin (PR) and NT 
in GT3 and GT4. A published Markov model (MONARCH) was used to simulate treat-
ment in a cohort (mean age 50 years, 67% male) over a lifetime, using established 
disease transition rates, costs and health utilities. UK 2013 costs were employed, 
with costs and benefits discounted at 3.5%. Weekly treatment costs and sustained 
virologic response (SVR) rates used were: DCV: £2,038.13; SOF: £2,915.24 (DCV+SOF 
SVR: 100% GT1, GT3 and GT4); TVR: £1,866.50 (SVR: 62%); PR: £191.35 (SVR: 58% 
GT3; 45% GT4). RESULTS: In GT1, incremental costs were £15,282 and £20,798 and 
incremental QALYs were 1.95 and 4.88 compared to TVR+PR and NT, respectively. In 
GT3, incremental costs were £96,953 and £78,478, with QALY gains of 2.50 and 5.85 
for PR and NT, respectively. In GT4, incremental costs were £26,966 and £18,636, with 
QALY gains of 3.07 and 5.36 for PR and NT, respectively. Predicted ICERs were: GT1, 
£7,830 versus TVR+PR, £4,263 versus NT; GT3, £38,815 versus PR, £13,416 versus NT; 
GT4, £8,782 versus PR, £3,477 versus NT. CONCLUSIONS: At conventional UK cost 
effectiveness thresholds, treatment with DCV+SOF is estimated to be cost-effective 
compared to standard of care and no treatment in GT1 and GT4 patients with 
advanced disease. In GT3, DCV+SOF is predicted to be cost-effective compared to NT.
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OBJECTIVES: The goal of hepatitis C virus (HCV) treatment is the attainment of 
sustained virologic response (SVR). As the predominant source of infection in the 
UK is associated with high-risk behaviour among people who inject drugs (PWID), 
reducing the infected population via treatment may prevent future infections. 
This study evaluated the health economic impact of two treatment regimens, 
daclatasvir+sofosbuvir (DCV+SOF) and telaprevir+pegylated interferon-alfa+ribavirin 
(TVR+PR), in a cohort of people with high transmission risk, when accounting for 
future infections avoided. METHODS: A combined dynamic HCV transmission and 
published disease progression model (MONARCH) was populated with published UK 
data for PWID. Future costs, life years and quality-adjusted life-years (QALYs) were 
discounted at 3.5%. A prevalence parameter amongst PWID of 25% was utilised and 
results presented per 1,000 patients. The impact of treating all (25/1000) or a propor-
tion (8/1000) of patients with DCV+SOF or TVR+PR within a one-year period was 
evaluated. Published SVR rates of 95% and 59% were applied to DCV+SOF and TVR+PR, 
respectively. RESULTS: Ignoring future infections, DCV+SOF was associated with 
incremental per-patient costs of +£18,166 and incremental benefits of +1.4 QALYs and 
an incremental cost-effectiveness ratio (ICER) of £9,867 compared to TVR+PR. When 
considering reduced transmission, additional per-patient discounted cost savings of 
£8,803 and QALY gains of 1.42 were estimated, from 1,845 future infections and 328 
related long-term complications avoided over the period 2015–2065 if all patients were 
treated. The associated ICER decreased from £9,867 to £2,869. Assuming 8/1000 PWID 
were treated, the ICER decreased from £9,867 to £8,156. CONCLUSIONS: Accounting 
for the impact of SVR on future disease transmission can significantly impact cost-
effectiveness results in HCV. Factoring in the consequences of infections avoided is 
imperative when evaluating the cost-effectiveness of HCV treatment among groups 
at high risk of transmission, such as PWID.
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OBJECTIVES: To systematically review economic evaluation studies of vaccination 
programs in China. METHODS: We did a computerized search of published full 
economic evaluations of Chinese vaccination programs (published prior to March 
16, 2014) in major English and Chinese databases. RESULTS: Seventeen economic 
evaluations of 8 vaccines were identified, and Hepatitis B vaccine (29%) and 7-valent 
pneumococcal conjugate vaccine (18%) were the most studied. All studies were 
model based, but half of them used simple decision tree. 59% adopted a societal 
perspective. Eleven (65%) studies used a lifetime time horizon. 71% used the 3% 
discounting rate for base case analysis, and 24% either did not discount health 
outcomes or cost, or did not explicitly report the discounting rate. Effectiveness and 
cost data in 88% and 41%, respectively, were from literature alone. All 8 studies with 
OBJECTIVES: Hepatitis C virus (HCV) affects 3 to 4 million people in the United 
States and is a major cause of liver failure, hepatocellular carcinoma, and liver 
transplantation. Treatment of HCV has changed substantially in the last 2 years, 
with the introduction of new direct-acting antiviral therapies, which have been 
shown to reach cure rates higher than 95%. However this new class of therapies 
come at a high price, and has consequently been widely criticized. As such, it is 
important to understand the economic implications of their introduction into the 
market. The objective of the current study is to evaluate the cost-effectiveness of 
one of the most promising of these new therapies, sofosbuvir + ledipasir + riba-
virin (SOF+LDV+R), as compared to the two previous standard of care treatment 
options for treatment naïve genotype 1 infected HCV patients. METHODS: Cost-
effectiveness analysis using a Markov model of the natural disease progression 
of HCV infection and impact of treatment. We use a simulated 20 year model of a 
hypothetical cohort of 1000 patients to assess the cost-effectiveness of sofosbuvir 
+ ledipasvir + ribavirin (SOF+LDV+R), boceprevir + pegylated interferon + ribavirin 
(BOC+P+R), and telaprevir + pegylated interferon + ribavirin (TVR+P+R). RESULTS: 
Over the 20-year time horizon, no treatment resulted in 9.76 QALYs and a total 
discounted cost of $41,434, while BOC+P+R resulted in 11.06 and $88,162, TVR+P+R 
in 11.08 and $92,150 and SOF+LDV+R in 11.79 and $74,477, respectively. That is, 
our analysis showed that BOC+P+R and TVR+P+R were strongly dominated, with 
SOF+LDV+R being the most cost-effective therapy. CONCLUSIONS: Despite the high 
price of SOF+LDV+R, this new therapy not only yields higher QALYs, but actually 
costs less than the previous standard of care treatments for treatment naïve geno-
type 1 HCV patients. These results have important economic and policy implications 
for the treatment of hepatitis C.
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OBJECTIVES: Candidemia incidence in Chile has been estimated around 0.33 
(0.21–0.47) per 1,000 admissions. The aim of this analysis is to assess the cost-
effectiveness of anidulafungin compared with currently licensed antifungal agents 
in the treatment of confirmed infection of candidemia or invasive candidiasis in 
Chile. METHODS: The analysis was made from third payer perspective; the model 
timeframe was within a 6-week inpatient follow-up period with an extrapolation 
to lifetime for those surviving the 6-week period. Non-neutropenic patients were 
assumed. A tree-decision model was used to estimate potential treatment costs 
of anidulafungin vs comparator agents. Clinical success, mortality and adverse 
events rates were taken from international literature. Drug costs were taken from 
local institutional report and nephrotoxicity cost from official document, con-
sidering hemodialysis as required procedure. Comparators were: anidulafungin 
(loading dose 200mg/day, maintenance 100mg/day), caspofungin (loading dose 
70mg/day, maintenance 50mg/day), micafungin (100mg/day), fluconazole (400mg/
day), voriconazole (loading dose 6mg/kg/twice daily, maintenance 200mg twice 
daily or 4mg/kg twice daily), conventional amphotericin B [CAMB] (1 mg/kg), and 
liposomal amphotericin B [LAMB] (3mg/kg/day). It was considered an average 
patient weight of 76.4 kg (SD 25.5kg). Results are expressed as incremental cost-
effectiveness ratio (ICER) US$ per life year gained (LYG) in 2014 US$ (exchange rate 
US$1= CLP$600). RESULTS: Total costs (drugs and hospital stay) associated with the 
treatment were: CAMB US$18,664; fluconazole US$15,327; micafungin US$17,210; 
voriconazole US$17,310; anidulafungin US$17,941; caspofungin US$18,619; LAMB 
US$24,794; number of life years gained were: 6.30, 6.52, 5.55, 6.77, 7.23, 6.03 and 
5.47, respectively. Caspofungin, Amphotericin B and LAMB were dominated by 
anidulafungin; ICER of anidulafungin compared to fluconazole, micafungin and 
voriconazole was US$3,729; US$436 and US$1,371, respectively. CONCLUSIONS: 
For the analyzed scenario with threshold per life-year gained over US$3,729, anidu-
lafungin is a cost-effectiveness therapy compared to micafungin, fluconazole, 
voriconazole and generates savings compared to CAMB, caspofungin and LAMB 
for candidemia in Chile
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OBJECTIVES: Compared to infection with HCV alone, patients co-infected with HIV 
have faster disease progression, increased mortality and reduced quality adjusted 
life expectancy (QALE). The objective of this study was to compare the cost-effective-
ness of novel DAA regimens for HCV genotypes (GTs) 1 and 3 (which predominate 
in the UK) in HCV/HIV co-infected patients. METHODS: A published and validated 
lifetime HCV Markov model was used to model a cohort of patients (mean age 
50 years; 50% female) evenly distributed across fibrosis stages F0–F4, using HIV 
co-infection specific transition rates. Presented is a comparison of 12 weeks of 
daclatasvir+sofosbuvir (DCV+SOF) to 24 weeks of sofosbuvir+ribavirin (SOF+RBV) 
in treatment-naïve patients. Clinical inputs were obtained from pivotal trials: ALLY-2 
for DCV+SOF (GT1 SVR: 80/83 [96.39%]; GT3 SVR: 6/6 [100%]) and PHOTON-1/2 for 
SOF+RBV (GT1 SVR: 182/226 [80.53%]; GT3 SVR: 52/57 [91.23%]). Weekly costs were 
DCV= £2,043.15, SOF= £2,915.24 and RBV= £66.95. Published disease state costs (UK 
2013) and health utility values were used; both costs and benefits were discounted at 
3.5%. RESULTS: In GT1 patients, the model predicted that discounted life expectancy 
(LE) and QALE would increase by 0.52 and 0.69 in DCV+SOF (LE= 18.90, QALE= 12.37) 
compared to SOF+RBV (LE= 18.37, QALE= 11.68), respectively. Overall predicted costs 
were lower with DCV+SOF (£316,716) versus SOF+RBV (£334,487). In GT3 patients, 
the model predicted that discounted LE and QALE would increase by 0.36 and 0.44 
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transition rates. Disease state costs were obtained from 2013 UK data, with discount-
ing set to 3.5%. Weekly costs were: DCV= £2,043.15, SOF= £2,915.24 and RBV= £66.95. 
Clinical inputs were obtained from a matching-adjusted indirect comparison 
(adjusts for baseline differences between trials) of ALLY-3 and VALENCE: SVRs for 
DCV+SOF and SOF+RBV, respectively, were 96.4% and 94.3% for treatment-naïve, 
83.2% and 78.6% for treatment-experienced and 88.8% and 85.2% for interferon-
ineligible intolerant patients). RESULTS: In all comparisons, DCV+SOF was pre-
dicted to be associated with reduced total costs and improved QoL versus SOF+RBV: 
Treatment naïve: DCV+SOF expected to be associated with cost savings of £12,903 
and QALY gains of 0.13. Treatment-experienced: DCV+SOF expected to be associated 
with cost savings of £13,701 and QALY gains of 0.24. Interferon-ineligible/intolerant: 
DCV+SOF expected to be associated with cost savings of £13,382 and QALY gains 
of 0.2. Versus no treatment, DCV+SOF is expected to be cost-effective (total cost 
£31,875 and QALY gain of 4.12; ICER of £7,743) for interferon-ineligible/intolerant 
patients. CONCLUSIONS: 12 weeks of DCV+SOF appears a cost-effective treatment 
option for patients with HCV genotype 3 in all modelled scenarios. When compared 
to 24 weeks of SOF+RBV, DCV+SOF was predicted to be dominant.
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OBJECTIVES: A 6-day, once-daily course of tedizolid, a novel oxazolidinone antibacte-
rial, demonstrated non-inferior efficacy and comparable safety to a 10-day course of 
twice-daily linezolid in ABSSSI. We examined the economic impact of tedizolid as an 
alternative to linezolid on hospitals and MCOs. METHODS: Cost implications of tedi-
zolid versus linezolid use were examined via cost-minimization analysis. Treatment 
durations for tedizolid and linezolid were modeled at 6 and 10 days, respectively, 
consistent with approved drug labels. ABSSSI patients were assumed to initiate par-
enteral (IV) therapy in the hospital and switch to oral formulations upon discharge to 
complete any remaining days of therapy (DOT). Inpatient linezolid DOT were derived 
from 2008-2012 the Truven MarketScan® claims and linked Hospital Drug Database 
(HDD). Adult patients with a primary or secondary diagnosis consistent with ABSSSI 
and ≥ 90 days continuous eligibility prior to admission were included in the analysis. 
Patients with ≤ 6 inpatient linezolid DOT were modeled as receiving the same inpa-
tient DOT with tedizolid; patients with 7-10 inpatient linezolid DOT were modeled 
as completing a 6-day course of tedizolid in hospital. Daily drug costs were based on 
lowest, published wholesale average cost and included preparation/administration 
costs. RESULTS: Of 3,329 ABSSSI hospitalizations identified in the HDD, 261 (7.1%) 
were treated with linezolid an average of 4.2 days; outpatient linezolid DOT were 
estimated at 5.8 days. Inpatient and outpatient tedizolid DOT were estimated at 3.8 
and 2.2 days, respectively. Average total drug costs for a 10-day course of linezolid 
were calculated as $2,816 per patient ($1,050 inpatient, $1,766 outpatient), compared 
to $1,562 ($910 inpatient, $652 outpatient) for a 6-day course of tedizolid. Inpatient 
and outpatient cost savings were maintained at linezolid daily costs at or above $213 
and $111, respectively. CONCLUSIONS: Tedizolid is expected to reduce antibacterial 
treatment costs, with the greatest impact occurring in the outpatient setting.
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OBJECTIVES: Adults ≥ 65 years account for most seasonal influenza-related hos-
pitalizations and deaths. A recent 32,000-participant, head-to-head RCT (FIM12, 
NCT01427309) demonstrated that a high-dose influenza vaccine (HD) was 24.2% more 
efficacious than a standard-dose influenza vaccine (SD) in adults ≥ 65 years. A cost-
utility analysis (CUA) of HD vs. SD in FIM12 participants was performed. METHODS: 
Health-care resource utilization data collected in the FIM12 study included: medica-
tions, non-routine medical and emergency room visits, and hospitalizations. Utilized 
resources were summarized across vaccine arms and unit costs were applied, using 
standard US cost sources, to each resource item (including vaccines; HD $31.82; SD 
$12.04) to estimate the mean total direct medical and societal costs associated with 
each vaccine. Adverse event data from the trial were mapped to quality of life data 
from the literature to estimate the effectiveness of both vaccines. The time horizon 
was one year’s influenza season for costs and a lifetime for quality-adjusted life 
years (QALYs). RESULTS: The average per-participant direct medical costs (including 
influenza vaccine cost) and societal costs were $116 and $128 lower in the HD arm. 
Hospitalizations represented over 95% of the total cost and were less frequent in the 
HD arm (7.7% of HD participants reported ≥ 1 hospitalization versus 8.4% in SD arm) 
and average length of stay (LOS) across all participants was shorter in the HD arm (0.49 
days vs 0.56 days). HD was associated with 0.0004 more QALYs per participant and, 
due to cost savings, dominated SD in the CUA. CONCLUSIONS: Despite the higher 
price of HD vs. SD, the total direct medical and societal costs were over $100 lower per 
vaccinee in those who received HD. This was driven by a reduction in the number of 
hospitalizations and in the LOS for those hospitalized. HD dominated SD in the CUA.
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OBJECTIVES: Pneumococcal infections are a public health problem in older adults. 
In Chile there are two vaccines at this time, PPSV23 and PCV13. The objective of 
QALYs outcome used utility data from other studies, of which only one used utilities 
generated in Chinese population. 29% of those with composite outcomes DALYs 
and QALYs included cases, deaths and life years at time. 47% considered indirect 
cost due to causes such as sick leave and loss of productivity in addition to direct 
cost for the analysis. All but one studies included sensitivity analysis, but 53% did 
not conduct probability sensitivity analysis to see the joint effect of uncertainties 
around multiple parameters. Six (35%) were post hoc studies assessing the cost-
effectiveness of current vaccination compared with the non-vaccination alterna-
tive. All studies except one on 7-valent pneumococcal conjugate vaccine showed 
cost-effectiveness for the vaccinations. CONCLUSIONS: Major methodological flaws 
and reporting problems exist in economic evaluations for vaccines in China. Local 
guidelines for good practice and reporting are demanded in addition to institutional 
mechanisms and education for improve the overall quality of economic evaluation 
work for immunization programs in China.
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OBJECTIVES: A regimen including nevirapine (NVP) is often the predominant 
antiretroviral therapy (ART) available for children infected with human immuno-
deficiency virus (HIV) in Africa, because it is inexpensive, stable at high tempera-
tures, and used as a single dose for the prevention of mother-to-child transmission 
(PMTCT) of HIV. Despite the benefits of NVP, challenges exist from the effect of NVP 
resistance in children who become infected with HIV regardless of prophylaxis. 
As a result of these concerns, ritonavir-boosted lopinavir (LPV/r) based regimens, 
although more expensive, are preferred by some clinicians over the less costly NVP-
based regimens. We therefore evaluated the cost-effectiveness of NVP-based regi-
mens to LPV/r-based regimens as a first-line treatment option for children with HIV 
after virologic suppression. METHODS: A Markov Model was designed to compare 
the cost-effectiveness of NVP-based regimens to LPV/r-based regimens for HIV-
infected children with three HIV transition states, CD4% > 15, CD4% < 15, and death. 
The clinical and costs data were collected from published studies of ART for children 
in South Africa and based on time horizons of one year and lifetime. RESULTS: The 
resultant Incremental Cost Effectiveness Ratio (ICER) from this study demonstrates 
that the NVP based strategy is cost effective, with the incremental cost and the 
incremental QALY of the time horizon of one-year and lifetime of, $690.15/0.92QALY 
and $22,578.25/30.27QALY respectively. CONCLUSIONS: For HIV infected children 
with a history of exposure to single dose NVP (sdNVP) from PMTCT prophylaxis, it 
is cost-effective to switch to NVP-based regimens as a first-line treatment option 
after virologic suppression with LPV/r based HAART.
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OBJECTIVES: To estimate the cost-effectiveness of rabies vaccination program in 
dogs to prevent human rabies in Colombia. METHODS: A Markov model with daily 
cycles was designed to simulate the dynamics of the transmission of rabies in 
the dog population of Colombia. A Literature review for identifying transmission 
parameters within dog population and transmission to humans was carried out. The 
model considered two alternatives: No vaccination and dog vaccination (comparing 
different vaccination coverage). The burden of disease in human population, during 
one year, in terms of years of life lost (YLL) was estimate and program and care costs 
were collected from a third payer perspective. Incremental cost effectiveness ratio 
(ICER) of vaccination versus no vaccination was estimated. All cost were adjusted 
to 2013 US dollars. RESULTS: With no vaccination 58,591 of dog rabies cases were 
estimated whit 5 human cases and 338 YLL. With vaccination at a 68% coverage and 
75% of vaccine effectiveness, 28,664 dog cases and 2 human cases were estimated. 
The vaccination costs were US $ 777,331.76; administration costs of US $ 1,426,463.00 
and wastage costs were estimated at US $ 77,733.18; for a total program cost of US 
$ 220,379,48. The variation in vaccination coverage, introduced significant changes, 
the most significant change is reflected in the costs to present a case of human 
rabies; with the current coverage is US $ 10,394.87 to $ 6,933.36 USD (90% coverage). 
The incremental cost effectiveness ratio (ICER) would be between 654 and 704 per 
additional year of life gained. CONCLUSIONS: Increase vaccination coverage in dogs 
to decrease the incidence of human rabies is a cost-effective strategy in Colombia.
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OBJECTIVES: Chronic infection with hepatitis C virus (HCV) genotype 3 is associated 
with faster disease progression and is considered difficult to treat. The objective 
of this investigation was to compare the cost-effectiveness of two new all-oral, 
interferon-free treatment regimens: daclatasvir plus sofosbuvir (DCV+SOF) and 
sofosbuvir plus ribavirin (SOF+RBV). Historically, patients ineligible for/intoler-
ant to interferon had no available treatment option; therefore, a comparison to no 
treatment was also made in these patients. METHODS: A published Markov model 
(MONARCH) was used to estimate the cost-effectiveness of treatment regimens 
over a lifetime horizon. Patients were evenly distributed across fibrosis stages F0–F4 
upon treatment initiation. Patients progress through disease stages using published 
